Mr. Haeng Gyu Lee is a partner in Jipyong LLC’s Finance Group and heads the Capital Markets Team. He is one of Korea’s highest ranking attorneys in capital markets (IPOs and de-listing reviews), private equity funds, M&A, overseas expansion of financial institutions, project financing, syndicated loans, and ABS, and has unparalleled experience in cross-border IPOs, GDR offerings and dual listings.
Mr. Lee’s most recent transaction highlight is his successful representation of SK Biopharmaceuticals in its recent IPO on the KOSPI market division of the Korea Exchange (KRX), the largest Korean IPO in 2020. SK Biopharmaceuticals, established in 2011, is an innovative chemical drug maker focusing on treating disorders of the central nervous system. As reflected in his significant track record, Mr. Lee is renowned for advising numerous companies that were first in their respective country of incorporation to be listed on the KRX, such as New Pride Corporation (US), Kolao Holdings (Laos), Fast Future Brands (Australia) and LS Cable & System Asia (Vietnam). Mr. Lee is currently representing Nanogen, Vietnam’s largest biosimilars company and Prestige Bio Pharma, a Singaporean biosimilars company on their respective listings on the KRX. Mr. Lee also currently serves as a legal advisor for the KRX and on KRX’s task force team to attract Asian companies of excellence to list on the KRX. He is also a member of the Corporate Evaluation Committee of the Stock Market Division of the KRX.
Jipyong LLC’s Capital Markets Team is anticipating another stellar year under Mr. Lee’s leadership. His key clients include major Korean securities houses, such as Korea Investment & Securities, Mirae Asset Daewoo, Samsung Securities, Daishin Securities, Kiwoom Securities and KB Securities.